We have previously demonstrated that interleukin-17A (IL-17) producing T helper 17 cells are significantly elevated in blood and bone marrow (BM) in multiple myeloma (MM) and IL-17A promotes MM cell growth via the expression of IL-17 receptor. In this study, we evaluated anti-human IL-17A human monoclonal antibody (mAb), AIN457 in MM. We observe significant inhibition of MM cell growth by AIN457 both in the presence and the absence of BM stromal cells (BMSCs). Although IL-17A induces IL-6 production, AIN457 significantly downregulated IL-6 production and MM cell adhesion in MM-BMSC co-culture. AIN457 also significantly inhibited osteoclast cell differentiation. More importantly, in the SCIDhu model of human myeloma administration of AIN457 weekly for 4 weeks after the first detection of tumor in mice led to a significant inhibition of tumor growth and reduced bone damage compared with isotype control mice. To understand the mechanism of action of anti-IL-17A mAb, we report, here, that MM cells express IL-17A. We also observed that IL-17A knockdown inhibited MM cell growth and their ability to induce IL-6 production in co-cultures with BMSC. These pre-clinical observations suggest efficacy of AIN457 in myeloma and provide the rationale for its clinical evaluation for anti-myeloma effects and for improvement of bone disease.
INTRODUCTION
Bone marrow (BM) micro-environments have been shown to have a critical role in multiple myeloma (MM) pathobiology. 1 Immune cells form an important component of this microenvironment, and are modulated by the conditions generated in the BM. 2 We have previously reported dysfunctional regulatory T cells 3 and an increased number of IL-17A-expressing T helper (Th17) cells in MM. 4 These immune abnormalities have been considered to favor tumor cell progression, both directly as well as by suppressing anti-MM immune responses. These immune changes also induce associated bone disease and predispose patients to immuneparesis and associated infectious complications. 5 Th cells have an important role in developing a robust and lasting immune response against bacterial, fungal and viral infections, as well as against tumor cells. Besides Th1, Th2 6 and T regulatory cells, 3, 7, 8 Th17 cells have an important role in immune protection against pathogens. [9] [10] [11] Furthermore, Th17 cells participate in mediating immunopathological manifestations of a number of autoimmune diseases. [12] [13] [14] [15] Interestingly, interactions between MM cells and the BM microenvironment lead to a production of a number of cytokines and chemokines (TGF-β, IL-6, IL-1β and IL-23) 1 that skew the Th cell subset differentiation to Th17 cells. The Th17 cells in turn, both directly and via pro-inflammatory cytokines produced by them, modulate tumor cell growth, suppress Th1 immune responses 4 and affect other components of tumor microenvironment, especially osteoid elements as in rheumatoid arthritis. 15, 16 Higher proportion of Th17 cells are induced from naive CD4 T cells in MM compared with healthy donors. 4 Dendritic cells also induce a higher number of Th17 cells in BM of MM patients. 17 Furthermore, serum levels of IL-17 are significantly elevated in MM compared with healthy donors and this increase is stage dependent. [18] [19] [20] [21] [22] IL-17 has also been shown to have a critical role in the genesis of bone disease in myeloma by mediating osteoclast (OC) formation and activation. 23, 24 On the other hand, bisphophonates treatment is shown to decrease serum levels of IL-17, thus reducing the bone damage reported in MM. 25 IL-17A induces significant increase in proliferation of MM cell lines and primary cells in vitro via IL-17A receptor 4 expressed on tumor cells and IL-17A pretreatment led to the development of significantly larger tumors compared with the control in murine xenograft model of MM. 4 Increased frequency of Th17 cells is also observed in a number of other human malignancies, including ovarian, prostate, renal and pancreatic carcinomas. [26] [27] [28] These studies provided the rationale to pre-clinically evaluate the effects of anti-IL-17A monoclonal antibody (mAb) on MM cell-growth both in vitro and in vivo. The results show that MM cell growth and survival are significantly inhibited by anti-IL-17A mAb both in vitro as well as in animal studies. IL-17A is produced by myeloma cells and its suppression affects myeloma cell growth indicating a possibility of an autocrine loop.
MATERIALS AND METHODS

Patient samples
from Dana-Farber Cancer Institute. Healthy donor BM samples were obtained from AllCells (Emeryville, CA, USA).
Myeloma cell-proliferation assays MM cells (MM1S, KMS-12PE, RPMI 8226, KMS-12BM, OPM-1, OPM-2, INA-6, H929, U226 and ARP1), cultured in RPMI 1640 supplemented with 10% fetal bovine serum and antibiotics for 3 days in the presence of isotype or anti-IL-17A mAb (10 μg/ml, AIN457, Novartis, Basel, Switzerland). Proliferation was measured by 3 H-thymidine incorporation and 3-(4,5-dimethylthiazol-2-yl)-2,5-dimethyltetrazolium bromide (MTT) assay (Life Technologies, Grand Island, NY, USA). Co-culture studies were performed with BM stromal cell (BMSC) in the presence of isotype control antibody or AIN457. IL-6 with or without AIN457 and its antibody with or without IL-17A (R&D Systems, Mineapolis, MN, USA) were used in co-culture to determine the growth and proliferation in these assays. Colony-forming assays were performed using MethoCult agar media (Stem Cell Technologies, Vancouver, BC, Canada) in the presence of isotype control antibody or anti-IL-17A mAb for 3 weeks. 4 Measurement of IL-6 production by IL-17A and inhibition by AIN457 using ELISA assays BMSC were cultured for 3 days in the presence or absence of IL-17A (100 ng/ml), IL-21, IL-22, IL-23, IL-27 and lipopolysaccharide at 10 ng/ml concentration. For antibody inhibitory studies, BMSC in the presence or absence of MM cell lines was cultured with isotype control antibody, or IL-17A, or anti-IL-17A mAb or in combination with IL-17A+anti-IL-17A mAb. For ex vivo studies, the fetal bone chips with MM cells were incubated in the presence of isotype control antibody or anti-IL-17A mAb for 2 days. Myeloma cells were co-cultured with BMSC in the presence of IL-17A with or without cell-signaling inhibitors (JAK2, STAT3, JNK, MEK, NFκB and PI3 inhibitors at 10 μM from Cell Signaling, Danvers, MA, USA). IL-6 production was measured by standard ELISA (R&D Systems). The immunohistochemical analysis of myeloma cells in the bones was performed by staining them with anti-CD138 antibodies. 4 
Adhesion assay
Cell adhesion assay was performed as previously described. 29 In brief, serum-starved MM cells (5 × 10 6 /ml) were first labeled with calcein (Molecular Probes, Eugene, OR, USA) and cultured with BMSC in the presence of isotype control antibody or anti-IL-17A mAb. The absorbance of each well was measured at 492/520 nm plate reader, as described. 4 
Osteoclast formation
As described earlier, 30 OCs were differentiated from bone-marrow mononuclear cells from healthy volunteers in six-well plates. Adherent cells were cultured for 21 days in alpha-minimum essential media containing with (positive control) or without (negative control) 50 ng/ml of macrophage colony-stimulating factor (R&D Systems) and RANKL (PeproTech, Rocky Hill, NJ, USA) with anti-IL-17A mAb or isotype control antibody at 10 μg/ml concentration. Cells stained for tartrate-resistant acid phosphatase (TRAP) using an acid-phosphatase leukocyte staining kit (Sigma Aldrich, St Louis, MO, USA).
Myeloma murine xenograft model
Six-to eight-week-old male Fox Chase CB-17 severe combined immunedeficient (SCID) mice (Charles River Laboratories Intl. Inc., Wilmington, MA, USA) were injected with five million OPM-1 myeloma cells with isotype or AIN457 (10 μg/ml) by subcutaneous route with approvals by the Institutional Animal Care and Use Committee (VA Boston Healthcare System). Tumor volume was measured at indicated time intervals as described previously. 31 In another set of experiments, SCID mice were treated with with weekly subcutaneous injections following MM cell injections. In addition, Balb/C mice were injected with murine plasmacytoma cell line (ATCC CCL167/MPC11) and treated with isotype control antibody or murine anti-IL-17A mAb (10 μg/ml) for a week with subcutaneous injections and tumor volumes were measured.
SCIDhu human myeloma model
Human fetal bone grafts were subcutaneously implanted into SCID mice (SCIDhu), as previously described. 32 Four weeks following bone implantation, 2.5 × 10 6 INA-6 MM cells were injected directly into the human bone implant. One group was treated with isotype control antibody and another group of mice was treated weekly subcutaneously with AIN457 (10 μg/ml) for 4 consecutive weeks following first detection of tumor. Tumor growth was evaluated by measuring serum level of soluble human IL-6R with ELISA (R&D Systems).
Micro-computed tomography analysis of bones
The bone damage caused by myeloma cells from these mice was assessed by micro-computed tomography analysis at the end of the study as described. 33 Quantitative PCR and western blot analysis Quantitative PCR was performed for IL-17A using RNA isolated from MM cell lines and purified MM primary cells. Results are presented as relative expression value in comparison with GAPDH. Cell lysates were probed with anti-sera to IL-17A and GAPDH (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Myeloma cell lines were stained with isotype control antibody or anti-IL-17A antibody and analyzed by confocal microscopy. One representative cell line of four experiments is shown at a magnification of × 640. 4 Small interfering RNA and short hairpin RNA transfections MM cells (U266) were transfected with small interfering RNA or short hairpin RNA or respective controls (Santa Cruz Biotechnology) for IL-17A and cultured to measure viability, colony formation and IL-6 levels with BMSC.
Statistical analysis
Statistical analyses were performed by Student's t-test. Po0.05 was considered statistically significant.
RESULTS
Growth inhibitory activity of anti-IL-17A antibody on myeloma As IL-17A promotes myeloma cell growth and survival, 4 we investigated the effects of human anti-IL-17A mAb (AIN457) in MM. As seen in Figure 1a , anti-IL-17A mAb significantly inhibited MM cell proliferation measured by 3 H-thymidine incorporation (−21.8 ± 2.14%, P o 0.05) compared with proliferation of MM cell lines with isotype control antibody. The inhibitory effect of anti-IL-17A mAb on myeloma cell growth (−16.2 ± 2.3, Po 0.05) compared with cell growth of MM cell lines with isotype control antibody was also observed using MTT assay (Figure 1b) . We observed that anti-IL-17A mAb significantly inhibited colony formation in methoCult colony assay (40 ± 5, P o 0.05, compared with isotype control antibody, 80 ± 4; N = 3) and with primary MM cells (N = 4; 31 ± 5, P o0.05, compared with isotype control, 84 ± 7; Figure 1c and d). These results suggest that anti-IL-17A mAb significantly inhibits growth of MM cell lines and primary cells in vitro. We also observed anti-IL-6 antibody in the presence of IL-17A significantly reduced growth and proliferation induced by IL-17A in co-culture with BMSC, however, it did not reach control level in both thymidine incorporation (Figure 1e ) and in MTT assays (Figure 1f ). On the other hand, adding IL-6 in the presence of anti-IL-17A antibody slightly increased growth and proliferation of myeloma cells in co-culture with BMSC and it did not restore the growth and proliferation of MM cells to the control level.
Downregulation of BMSC-mediated MM cell growth by anti-IL-17A antibody via blockade of IL-6 production We evaluated the influence of anti-IL-17A mAb on BMSC-mediated MM cell growth. As seen in Figure 2a , anti-IL-17A mAb significantly inhibited MM cell proliferation (−22.7 ± 2.9%, Po 0.05) in the presence of BMSC compared with MM cell proliferation in the presence of BMSC with isotype control antibody in co-culture assays as measured by 3 H-thymidine incorporation.
It is well established that IL-6 produced by MM-BMSC interaction mediates MM cell growth. So we further investigated whether IL-17A affects IL-6 production by BMSC alone or in coculture assays and whether anti-IL-17A mAb mediates part of its activity via its effect on IL-6 produced by BMSC. We evaluated the effect of the number of cytokines associated with Th17 proinflammatory pathway (IL-21, IL-22, IL-23, IL-27 and TGF-β) on IL-6 production by BMSCs. As seen in Figure 2b , only IL-17A, in addition to lipopolysaccharide used as a positive control, was able to induce significant increase in IL-6 production by BMSC compared with endogenous or baseline IL-6 production by BMSC without lipopolysaccharide. We further evaluated the influence of anti-IL-17A mAb on IL-17A-induced IL-6 production by BMSC alone or in co-culture systems. As seen in Figure 2c , IL-17A was able to significantly increase IL-6 production by BMSC alone (360 ± 37% increase compared with endogenous IL-6 production by BMSC alone, P o 0.05, in the left side of Figure 2c ) and in co-culture with MM cells (514 ± 76% increased compared with endogenous levels of IL-6 by BMSC alone and co-culture controls, P o 0.05, in the right of Figure 2c ). Although, anti-IL-17A mAb was able to significantly decrease (P o 0.05) the IL-6 production by BMSC (77 ± 4.5%, in the left side of Figure 2c ) compared with endogenous levels of IL-6 by BMSC alone with isotype control antibody and in co-culture system (107 ± 9% in the right of Figure 2c ) compared with endogenous levels of IL-6 in co-cultures with isotype control antibody (212 ± 32%). In addition, when we used anti-IL-17A mAb+IL-17A in combinational studies, we observed that anti-IL-17A mAb was also able to reduce The number of colonies were counted in unit area and presented as mean ± s.e.m. *P o0.05. Myeloma cells (U266) was co-cultured with BMSC for 3 days in the presence of isotype, IL-17A with or without anti-IL-6 (10 μg/ml) antibody, and anti-IL-17A antibody with or without IL-6 (10 ng/ml) and proliferation was measured by thymidine incorporation (e) and MTT (f) assays. Data are presented as percentage control co-culture proliferation and showed as mean ± s.e.m.
significantly IL-6 production in the presence of IL-17A, (142 ± 18% compared with IL-6 production by BMSC with IL-17A with isotype control antibody, 360 ± 37%, in the left side of Figure 2c ) and in co-culture (245 ± 33% compared with IL-6 production in co-culture with IL-17A with isotype control antibody, 514 ± 76%, in the right of Figure 2c ). We next evaluated the effect of anti-IL-17A mAb on the ability of myeloma cells to bind to BMSC using established adhesion assay. Calcein-labeled MM cells were co-cultured with BMSC for 4 h and adhesion was measured as described in methods. Presence of anti-IL-17A mAb (N = 3) significantly reduced (27 ± 3.8%, P o 0.05) MM-BMSC adhesion as compared with the adhesion of MM cells to BMSC in the presence of isotype control antibody as measured by the absorbance using a fluorescence plate reader (Figure 2d ). Finally, when we injected Th17 pathway in myeloma RH Prabhala et al MM cells ex vivo into human fetal bone chips, IL-6 production was significantly reduced in the presence of anti-IL-17A mAb, compared with IL-6 production in the presence of isotype control antibody after 48 h (Figure 2e ). Analysis of these bone chips by immune histochemistry using anti-CD138 mAb showed significant reduction of CD138 + expression (dim or low) of plasma cells by anti-IL-17A mAb compared with CD138 + expression (bright or high) in the presence of isotype control antibody (Figure 2f ). When myeloma cells were co-cultured with BMSC in the presence of IL-17A with or without different cell-signaling inhibitors (JAK2, Figure 2 . Downregulation of BMSC-mediated MM cell-growth by anti-IL-17A antibody via blockade of IL-6 production. (a) MM cell lines (N = 7) were cultured with BMSCs in the presence of isotype control antibody or anti-IL-17A mAb and proliferation measured by 3 H-thymidine incorporation after 3 days and presented as percentage of inhibition in proliferation with isotype control antibody. (b) BMSC was cultured for 3 days in the presence or absence of IL-17A (100 ng/ml), IL-21, IL-22, IL-23, IL-27 and LPS at 10 ng/ml concentration. IL-6 production was measured by standard ELISA (R&D Systems). Bar graph represents mean ± s.e.m. of the data (N = 4) calculated as percent of increase or decrease in IL-6 levels in culture supernatants compared with IL-6 levels (as endogenous IL-6 production) obtained from BMSC alone without any stimulation. (c) BMSC in the presence (right or absence (left) of MM cell lines was cultured with isotype control antibody, IL-17A or anti-IL-17A mAb or in combination with IL-17A+anti-IL-17A mAb and IL-6 levels were measured in culture supernatants by ELISA. Bar graph represents mean ± s.e.m. of the data calculated as percent of increase or decrease in IL-6 levels in culture supernatants compared with IL-6 levels (as endogenous IL-6 production) obtained from BMSC alone with isotype control antibody without any stimulation. ** indicates that AIN457-mediated reduction of IL-6 levels are statistically significant (Po 0.05) compared with co-culture IL-6 levels. *** indicates statistical significance (Po 0.05) between the two bars shown by the horizontal line. (d) Serum-starved MM cells were labeled with calcein AM, washed and added to BMSC-coated plates in the presence of isotype control antibody or anti-IL-17A mAb for 4 h and non-adherent cells were removed by washing. Adhesion was measured by measuring the absorbance using 492/520 nm filter set with a fluorescence plate reader. Results represent mean ± s.e.m. of three independent experiments performed in triplicate. The absorbance values obtained with isotype control antibody was considered as 100% and percentage of inhibition was calculated for anti-IL-17A treatment. (e) The fetal bone chips with MM cells were incubated in the presence of isotype control antibody or anti-IL-17A mAb for 2 days for ex vivo for the evaluation of IL-6 production that is measured by ELISA (R&D Systems). Bar graph represents mean ± s.e.m. of the data calculated as percent of IL-6 levels (as endogenous IL-6 production) in culture supernatants from BMSC alone with isotype control antibody. Reduced osteoclast cell numbers by the antibody. Normal BM cells were cultured for 3 weeks in osteoclast-supporting medium (consisting 25 ng/ml of macrophage colony-stimulating factor and 25 ng/ml of receptor activator of nuclear factor kappa-B ligand) with isotype control antibody (as positive control) or anti-IL-17A antibody and the tartrate-resistant acid phosphatase (TRAP+) multinucleated osteoclast cells were stained and cell numbers were counted. Cells were cultured without osteoclast-supporting medium as negative control.
Images were obtained at magnifications of × 10 with microscope (Eclipse TS100, Nikon) with spot insight camera. TRAP-positive cells containing five or more nuclei/cell were enumerated using image J 1.45 software (NIH, Bethesda, MD, USA). A representative image was depicted in (a) and composite results from three experiments were shown in bar graph (b). * indicates statistical significance (Po 0.05). There were no significant differences observed among three groups in cell viability measured with alamor blue staining.
STAT3, JNK, MEK, NFkB and PI3 inhibitors), IL-6 production was significantly inhibited by all of these signaling pathway inhibitors except STAT3.
Downregulation of OC development in vitro by ant-IL-17A mAb IL-17 has also been shown to have a critical role in the genesis of bone disease in myeloma by mediating OC formation and activation. 23, 24 Normal bone-marrow mononuclear cells were cultured for 3 weeks in OC-supporting medium with isotype control antibody or anti-IL-17A mAb, and stained for TRAP+ multinucleated OC cells. TRAP-positive stained cells containing five or more nuclei/cell were enumerated with the aid of microscope and image J software (National Institutes of Health, Bethesda, MD, USA). A representative image was depicted (Figure 3a) showing pink cells as TRAP + multinucleated OCs in positive control in the presence of isotype control antibody as compared with anti-IL-17A mAb-treated group showing osteoblast-looking growth patterns. As seen in Figure 3b , the OC cell number was significantly decreased (by 42%) by anti-IL-17A mAb treatment (23 ± 4) compared with the positive control with isotype control antibody (55 ± 4; P o0.05) in OC-supporting media.
Inhibition of human myeloma cell growth in vivo by systemic administration of anti-IL-17A mAb in murine models of human myeloma Next, we evaluated the efficacy of anti-IL-17A mAb in animal models using two different animal models of human myeloma. Initially in xenograft model, SCID mice were injected with myeloma cells along with isotype control antibody or AIN457 subcutaneously. Tumor volumes were measured at 24-and 30-day time intervals after MM cell injections. As seen in Figure 4a , in a representative of two experiments, the presence of anti-IL-17A mAb significantly reduced tumor size (37% inhibition at 24 days and 47% inhibition at 30 days, P o 0.05) compared with the tumor volumes in the presence of isotype control antibody treatment group at both time points evaluated. The reduction in tumor volumes by anti-IL-17A mAb may be due to either inhibiting tumor growth or tumor engraftment in this animal model. In another set of experiments, SCID mice were treated with weekly subcutaneous injections following MM cell injections. Even though we observed that anti-IL-17A mAb reduced (by 35% at 24 days after MM cell injection) myeloma growth in this SCID xenograft mice study and the difference in tumor volumes between isotype control antibody (2007 ± 584 mm 3 ) and treated groups (1299 ± 282 mm 3 ) is not statistically significant, as seen in Figure 4b . To evaluate the efficacy of anti-IL-17A mAb in immune competent mice, Balb/C mice were injected with murine plasmacytoma cell line (ATCC CCL167/MPC11) and treated with isotype control antibody (N = 13) or murine anti-IL-17A mAb (N = 20; 10 μg per mice) for a week and their tumor volumes were measured. However, we observed that anti-IL-17A mAb reduced (by 32%) myeloma growth in this immune competent mice study and the difference in tumor volumes between the isotype control antibody (1217 ± 207 mm 3 ) and the treated groups (827 ± 113 mm 3 ) was not statistically significant by the Student's t-test evaluation. Next, we evaluated the efficacy of anti-IL-17A mAb in the SCIDhu animal model of human myeloma. This model represents human myeloma development in the presence of BMSC. SCID mice were transplanted with human fetal bone chips, and after 4 weeks, myeloma cells were injected into the fetal bones. Following the first detection of the tumor, one group of mice was treated with human immunoglobulin G isotype control antibody and the other group of mice was treated with anti-IL-17A mAb (10 μg/mouse/injection) subcutaneously with weekly injections, for 4 weeks. Serum samples were collected weekly and level of human soluble IL-6R was measured by standard commercially available ELISA as a measure of tumor growth. 29 As seen in Figure 5a , a representative of two experiments, anti-IL-17 mAb significantly inhibited (by five times lower) tumor growth (5.9 ± 2.8 ng/ml of sIL-6R) compared with isotype control antibody (30.9 ± 10.5 ng/ml of sIL-6R) mice (P o 0.05). This SCIDhu human myeloma model is very similar to human myeloma conditions with its BM microenvironmental settings. The efficacy of this anti-IL-17A mAb in this SCIDhu human myeloma against myeloma cells is excellent by inhibiting 81% of myeloma cells ability to produce soluble IL-6 receptor while they are growing. We have used this SCIDhu human myeloma model for evaluating pre-clinical efficacy of number of agents, including chemotherapeutic agents and antibodies. In our pre-clinical efficacy evaluation studies using the SCIDhu human myeloma model over the past decade, the anti-IL-17A mAb was shown to be the best and have the highest efficacy against myeloma. We are seeing statistically significant differences between isotype control antibody and anti-IL-17A mAb-treated mice, and as results are confirmed in two different animal models, we believe that it provides adequate evidence for clinical evaluation of anti-IL-17 mAb in MM. In addition, anti-IL-17A mAb was also able to prevent the bone resorption caused by MM cells. At the termination of the experiment, micro-computed tomography studies of the human bones harvested from animals reveals protection by anti-IL17A from the bone resorption associated with myeloma tumor growth in the presence of isotype control antibody as seen in Figure 5b . The measurements of bone resorption showed that the prevention of resorption is significantly higher by the anti-IL-17A mAb treatment group compared with isotype control antibody treatment group (Figure 5c) .
Expression of IL-17A in myeloma cells and functional consequences by knockdown with small interfering RNA and short hairpin RNA on growth and survival of myeloma cells. To validate the expression of IL-17A by MM cells, we performed quantitative real-time-PCR in both MM cell lines and CD138+ primary MM cells from patients. We observed the expression of IL-17A in majority of MM cell lines as well as primary MM cells (Figure 6a and b) . The IL-17A expression was higher in five out of seven tested MM cell lines compared with the expression of IL-17A in PBMC collected from healthy donor. Expression of IL-17A protein was confirmed by western blot in all MM cell lines and seven out of nine purified primary MM cells (Figure 6c and d) . The IL-17A protein levels were lower in CD138+ primary MM cells compared with cell lines and Th17 cells as a positive control. Normal CD138+ cells collected from healthy donors have shown no IL-17A protein. Finally, we also show intracellular IL-17A protein in MM cells by confocal microscopy (Figure 6e) .
In order to investigate the functional consequences of IL-17A expression by MM cell line (U266), we evaluated the impact of IL-17A knockdown on MM cell growth and colony formation. IL-17A knockdown, using IL-17-specific small interfering RNA (Figure 7a ) inhibited MM cell growth as well as colony formation in MethoCult agar plates (Figure 7c ). We also confirmed these results using IL-17A-specifc short hairpin RNA (Figure 7b ). IL-17A induces IL-6 production by stromal cells alone and in co-culture settings as seen in Figure 2 . So, we evaluated the impact of IL-17A knockdown on IL-6 production by BMSC. IL-6 production in MM/ BMSC co-culture was significantly reduced following IL-17A knockdown in MM cells (Figure 7d ). These results show that IL-17A expressed by MM cells have an impact on the growth of MM cell as well as on the microenvironment. Figure 5 . Inhibition of tumor growth and prevention of bone resorption by AIN457, IL-17A antibody in SCID human myeloma model. (a) SCID mice were transplanted with human fetal bones, and after 4 weeks, myeloma cells were injected into the bones. One group was treated with vehicle with isotype control antibody and another group of mice were treated subcutaneously with AIN457 (10 μg/ml/mouse/injection) for 4 weeks following first detection of tumor by measuring human soluble IL-6R in the serum. Serum samples were collected weekly and level of human IL-6R was measured by ELISA. Baseline values before treatment were not significantly different among groups. Representative of two experiments is shown (P o0.05). (b) Treatment with anti IL-17A protects implanted bones from osteolysis. At the termination of the experiment, implanted human bones were excised and imaged by micro-computed tomography (microCT). Shown are the three-dimensional reconstructions of the bones and sections sliced longitudinally through the midpoint of each specimen injected with MM cells followed by treatment of the animal with either isotype control antibody (excessive bone resorption is seen) or anti IL-17A (no bone resorption is observed, trabecular bone is intact). The areas of increased osteoclastic bone resorption in the isotype control antibody-treated sample are indicated by arrowheads. Scale bar = 1 mm 3 . Anti-IL-17A antibody reduced the bone resorption caused by myeloma cells. (c) Significant differences in the measurements of bone resorption following anti-IL-17A mAb treatment. DISCUSSION IL-17A, a key pro-inflammatory cytokine, is predominantly produced by Th cells in addition to other immune cell types, including γδ and CD8+ T cells and NKT cells. 34 Although it provides protective effects against intracellular bacterial/viral, fungal and parasitic infectious agents, 9 it has a deleterious role in immune pathology of autoimmune 13 and inflammatory diseases including asthma, 35 in addition to cancer. [26] [27] [28] 36 The demonstration of elevated levels of Th17 cells and serum IL-17A in myeloma may help explain the reported higher incidence of MM in patients with autoimmune diseases. Our recent data also suggests elevated levels of other Th17-associated pro-inflammatory cytokines including IL-21, IL-22 and IL-23 in both peripheral blood and BM sera samples from MM compared with control samples. 4 Moreover, IL-17A induces MM cell proliferation with or without BMSC and increases MM cell adhesion to BMSC. 4 The presence and requirement of IL-17A receptor on MM cells further supports the role of IL-17A in MM cell growth and survival, and confirms it as a novel therapeutic target. IL-17A effects on immunoparesis in myeloma with suppressed Th1 responses in the presence of IL-22 4 and its activating effects on OC with consequent effect on bone disease in myeloma, 23, 24 provide added rationale to the target IL-17A in MM.
Here, we have evaluated the pre-clinical efficacy of human anti-IL-17A mAb on MM in vitro and in vivo. We observe that anti-IL-17A mAb significantly inhibit the growth of MM cell lines, as well as primary cells, and are able to overcome protective effects of BMSCs. The observed effects of anti-IL-17A mAb on MM cells in culture as well as in colony assay are intriguing and raise the question about the source of IL-17A in this system. In MM, we and others, have shown that IL-17A supports the MM cell growth and survival. 4, 17, 23 Further disease progression was observed with increased IL-17A serum levels. [18] [19] [20] [21] [22] Reduction of IL-17 after bisphosphonate treatment has also been reported. 25 These studies point out a significant role for IL-17A modulation in myeloma therapeutics.
It has been well established that IL-17A may cause its deleterious pathological effects through the increased production of IL-6, particularly in rheumatoid arthritis. 37, 38 We have shown for the first time that MM IL-17A induces IL-6 production by BMSC alone and in co-culture with MM cells. In addition, these results indicate that the other pro-inflammatory cytokines associated with Th17 cells, including IL-21, IL-22, IL-23 and IL-27, do not induce the IL-6 production by BMSC. We observed that anti-IL-17A mAb was able to significantly downregulate MM-BMSC adhesion and IL-6 production. These results were consistent with previous observations that IL-6 production was elevated in stroma in tissues. 38 In order to show the importance of IL-17A in the production of IL-6 in co-culture settings, neutralization studies showed that anti-IL-6 antibody did not completely inhibit IL-17A effects and adding IL-6 did not restore AIN457 inhibition on the growth and proliferation of MM cells. These studies taken together indicate that IL-17A-mediated growth and proliferation MM cells are in part mediated by IL-6 and in part mediated other factors. IL-17A induces number of pro-inflammatory factors in addition to IL-6. 38 As elevated levels of IL-6 and MM-BMSC interaction are involved in bone damaging effects during the progression of myeloma disease, inhibition of effects of IL-17A on IL-6 production can help improve bone disease in MM. IL-17A increases OC differentiation and thereby is partly responsible for associated bone damages observed in rheumatoid arthritis 39, 40 and IL-17 has also been shown to have a critical role in the genesis of bone disease in myeloma by mediating OC formation and activation. 23, 24 Therefore, we evaluated and observed significant inhibition of TRAP+ multinucleated OC cell differentiation by anti-IL-17A mAb. These results are in agreement with the recent report showing that the elevated levels of IL-17A and IL-1β in the BM plasma correlate with lytic bone disease in MM patients. 23 We have also observed anti-MM activity of anti-IL-17 mAb in two murine models of myeloma; the subcutaneous MM xenograft model, where a pre-treatment with anti-IL-17 mAb led to Th17 pathway in myelomasignificant reduction in tumor volume, and more importantly in the SCIDhu model of human MM cells. In the second model the results are especially interesting as we have a human microenvironment in this setting providing some of the cellular components of the human BM microenvironment. A number of studies have described increased frequency of Th17 cells in other human malignancies including, ovarian, prostate, renal and pancreatic carcinomas. [26] [27] [28] Moreover, IL-17 has also been linked to poor survival in a number of other cancers, including acute myeloid leukemia, breast, colorectal, liver, lung and melanoma. [40] [41] [42] We have shown that myeloma cells express IL-17 in many ways, including western blot and quantitative PCR assays, in addition to confocal microscopy. In human studies, transduction of IL-17 in three different non-small cell lung cancer cell lines, also expressing IL-17 receptors, led to significant increase in tumor growth in SCID model compared with control cells suggesting possible role of autocrine loop in these cancer cells. 43 Similar in vitro and in vivo results have been also reported in cervical cancer suggesting a role for IL-17A expression by tumor cells. 44 Conversely, regardless of the source of IL-17, IL-17 receptor deficiency has been reported to show reduced number of invasive prostate adenocarcinoma with lower rate of cellular proliferation suggesting that IL-17-mediated signaling promotes tumor growth. 45 These studies collectively suggest that expression of IL-17A and its receptors by tumor cells may affect their growth. In our setting it appears that MM cells inherently express both IL-17R as we have previously reported, 4 and also IL-17A as reported here. We have also observed the functional impact by IL-17A knockdown on tumor cell growth, as well as on supporting BM microenvironment. The impact of IL-17A produced by MM cells on BMSC is also very intriguing. Induction of IL-6 in BMSCs, by MM cell-derived IL-17A, may suggest in part a unique pathway for IL-6 production. A report of IL-17 production by MM cell may provide an explanation of the source IL-17 in this system. 46 Moreover, we have shown earlier, 4 using various methods, that MM cells do express IL-17 receptors, suggesting a possible autocrine loop is in play in MM using IL-17A and its receptor pathway. IL-17R-mediated pathways are very complex due to the presence of five different IL-17R and warrant further confirmative studies. The efficacy of neutralization of IL-17A in a variety of disease states, including asthma and lung inflammatory diseases, 47 rheumatoid arthritis 48, 49 and multiple sclerosis 50 where IL-17A participates in the development and/or pathophysiology disease, has been shown in addition to other cytokine targets in Th17 pathway. 51, 52 IL-17A is present in synovial fluids in rheumatoid arthritis and it participates in bone erosion. 53 Efficacy of anti-IL-17A mAb has been confirmed in three proof-of-concept trials recently; clinically significant improvements were observed in patients with psoriasis, rheumatoid arthritis and uveitis, where IL-17A has been implicated in the disease process without major adverse effects. 54 The second trial evaluating patients with rheumatoid arthritis where anti-IL-17A mAb, ixekizumab (LY2439821), showed improved signs and symptoms of rheumatoid arthritis without strong adverse effects 55 against psoriasis. 56 The third study is a phase 2, randomized, double-blind, placebo-controlled dose-ranging study of brodalumab (AMG 827), a human anti-IL17-receptor mAb for psoriasis. 57 In summary, we show that the anti-IL-17A mAb (AIN457) is able to inhibit MM growth and survival both in vitro and in vivo studies by blocking in part, positive autocrine feedback loop in addition to inhibiting IL-6 production by BMSC; it improves bone defects in MM and has the potential to improve immune function in MM. These results confirm the rationale for clinical evaluation of anti-IL-17 mAb in MM.
